Sign In
Last checked at 
19 Sep 2011 07:00
19 September 2011
Allergy Therapeutics plc
("Allergy Therapeutics" or "the Company")
Allergy Therapeutics Extends Anapen©Distribution Agreement
into UK and Ireland
Allergy Therapeutics plc (AIM: "AGY" or the "Company"), a fully integrated global specialty pharmaceutical company specialising in allergy vaccines, is pleased to announce that it has obtained the exclusive distribution rights in the UK and Ireland for the epinephrine pen auto injector, Anapen®, for a payment of £600,000. The agreement term is initially for 5 years and will commence on 1st November 2011.
Anapen®, produced by Lincoln Medical Limited, is indicated for the treatment of anaphylactic shock. Anaphylactic shock is a life threatening allergic reaction with increasing prevalence in all developed countries. Anapen® is the only epinephrine pen auto injector in the world with a 500 micrograms presentation. The 500 microgram presentation is indicated for people weighing above 65kg, giving Anapen® a strong competitive advantage.
The epinephrine pen auto injector market in the UK is valued at around £20 million and grew by 20% last year. Anapen® is already launched in the UK and Ireland and Allergy Therapeutics expects sales of up to £2 million in those countries during the next 12 months. Anapen® will be an important new product for Allergy's UK sales force and is targeted at similar physicians to those prescribing the Company's lead product Pollinex Quattro for the treatment of allergic conditions.
Allergy Therapeutics has been selling Anapen® in The Netherlands since September 2010 and has also received the exclusive rights to distribute Anapen® in Italy, Spain, Belgium, Poland, Argentina, Venezuela, Colombia and Chile, all countries with promising market potential. The Company expects to launch Anapen® in these countries during the next 12 months, subject to regulatory approvals.
-Ends-
For further information
Allergy Therapeutics | +44 (0) 1903 845 820 |
Manuel Llobet, Chief Executive Officer | |
Ian Postlethwaite, Finance Director | |
www.allergytherapeutics.com | |
Nomura Code Securities - NOMAD | +44 (0) 207 776 1200 |
Juliet Thompson/ Clare Terlouw | |
Financial Dynamics | +44 (0) 207 831 3113 |
Jonathan Birt/ Susan Quigley |
About Allergy Therapeutics
Allergy Therapeutics is a specialty pharmaceutical company focused on allergy vaccination. It has a growing business achieving sales of allergy vaccines in the prior financial year of £42 million mainly in Europe through its own sales and marketing infrastructure and further afield through distributors. The Company is expanding its infrastructure into the Emerging Markets.
Follow the stocks
